Individualizing therapy in gastric cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 4, 2003, Pages 457-470

  Sendler, Andreas ^a   Siewert, J Rüdiger ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Dissection surgery; Gastric neoplasm; Neoajuvant chemotherapy; Sentinel node

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; EDOXANA; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GADOLINIUM; METHOTREXATE; MITOMYCIN;

ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENDOSCOPIC SURGERY; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; LASER SURGERY; LONG TERM CARE; LYMPHADENECTOMY; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL GASTRECTOMY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; STOMACH BIOPSY; STOMACH CANCER; TOTAL STOMACH RESECTION;

EID: 0042510816     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.4.457     Document Type: Review

References (66)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80, 827-841 (1999).
2. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83, 2049-2053 (1998).
3. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340, 825-831 (1999).
4. Siewert JR, Fink U, Sendler A et al. Gastric cancer. Curr. Probl. Surg. 43, 837-937 (1997).
5. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat. Rev. 26, 243-255 (2000).
6. Siewert JR, Sendler A. The current management of gastric cancer. Adv. Surg. 33, 69-93 (1999).
7. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br. J. Surg. 85, 1457-1459 (1998).
8. Ishigami S, Natsugoe S, Hokita S et al. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J. Clin. Gastroenterol. 32, 41-44 (2001).
9. Rösch Th. Endosonographic staging of gastric cancer: a review of literature results. Gastrointest. Clin. N. Am. 3, 549-557 (1995).
10. Lightdale CJ. Endoscopic ultrasonography in the diagnosis, staging and follow-up of esophageal and gastric cancer. Endoscopy 24(Suppl. 1), 297-303 (1992).
11. Sohn KM, Lee JM, Lee SY et al. Comparing MR imaging and CT in the staging of gastric carcinoma. AJR Am. J. Roentgenol. 174, 1551-1557 (2000).
12. International Union Against Cancer. TNM classification of malignant tumours, 6th edition. Springer Verlag Berlin Heidelberg, NY, USA (2002).
13. Sendler A, Dittler HJ, Feussner H et al. Preoperative staging of gastric cancer as precondition for multimodal treatment. World J. Surg. 19, 501-508 (1995).
14. Weiss M, Eder M, Bassermann R. Charakterisierung verschiedener magenkarzinomtypen mit unterschiedlicher metastasierung in leber, peritoneum und knochen. Pathologe 14, 260-264 (1993).
15. Fuchs CS, Mayer RJ. Gastric carcinoma. N. Engl. J. Med. 333, 32-41 (1995).
16. Rode A, Bancel B, Douek P et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT and MRI and correlation with pathologic examination of explanted liver. J. Comput. Assist. Tomogr. 25, 327-336 (2001).
17. Burke EC, Karpeh MSJ, Conlon KC, Brennan MF. Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome. Ann. Surg. Oncol. 5, 411-415 (1998).
18. Feussner H, Omote K, Fink U, Walker SJ, Siewert JR. Pretherapeutic laparoscopic staging in advanced gastric carcinoma. Endoscopy 31, 342-347 (1999).
19. Lerut T, Flamen P, Ectors N et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann. Surg. 232, 743-752 (2000).
20. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br. J. Cancer 78, 521-527(1998).
21. Yoshioka T, Yamaguchi K, Kubota K et al. Evaluation of (18)F-FDG PET in patients with advanced, metastatic or recurrent gastric cancer. J. Nucl. Med. 44, 690-699 (2003).
22. Weber WA, Ott K, Becker K et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J. Clin. Oncol. 19, 3058-3065 (2001).
23. Siewert JR, Böttcher K, Roder JD et al. Prognostic relevance of systematic lymph node dissection: results of the German Gastric Carcinoma Study 1992. Br. J. Surg. 80, 1015-1018 (1993).
24. Siewert JR, Kestlmeier R, Busch R et al. Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br. J. Surg. 83, 1144-1147 (1996).
25. Ohgami M, Kumai K, Wakabayashi G, Otani Y, Katajima M. Innovative treatment for early gastric cancer: laparoscopic wedge resection of the stomach using the lesion-lifting method. Stomach Intestine 28, 1461-1468 (1993).
26. Yanai H, Matsumoto Y, Harada T et al. Endoscopic ultrasonography and endoscopy for staging depth of invasion in early gastric cancer: a pilot study. Gastrointest. Endosc. 46, 212-216 (1997).
27. Siewert JR, Böttcher K, Stein H, Roder JD and the German Gastric Carcinoma Study Group. Relevant prognostic factors in gastric cancer. Ann. Surg. 228, 449-461 (1998).
28. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br. J. Cancer 71, 587-591 (1995).
29. Stein HJ, Sendler A, Siewert JR. Site-dependent resection techniques for gastric cancer. Surg. Oncol. Clin. N. Am. 11, 405-414 (2002).
30. Japanese Gastric Cancer Association. Japanese classification of gastric cancer. Gastric Cancer 1, 10-24 (1998).
31. Maruyama K, Gunven P, Okabayashi K, Sasako M, Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann. Surg. 210, 596-602 (1989).
32. Lee KY, Noh SH, Hyung WJ et al. Impact of splenectomy for lymph node dissection on long-term surgical outcome in gastric cancer. Ann. Surg. Oncol 8, 402-406 (2001).
33. Sano T, Kobori O, Muto T. Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br. J. Surg. 79, 241-244 (1992).
34. van de Velde CJH, Peeters KCMJ. The gastric cancer treatment controversy. J. Clin. Oncol. 21, 2234 (2003).
35. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br. J. Cancer 79, 1522-1530 (1999).
36. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph node dissection for gastric cancer. Dutch Gastric Cancer Group. N. Engl. J. Med. 340, 908-914 (1999).
37. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Quality control of lymph node dissection in the Dutch randomized trial of D1 and D2 lymph node dissection for gastric cancer. Gastric Cancer 1, 152-159 (1998).
38. Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 123, 573-578 (1998).
39. Hartgrink HH, van de Velde CJ. Final results of the Dutch D1 versus D2 gastric cancer trial. Proc. Int. Gastric Cancer Congress 68 (2003) (Abstract).
40. Natsugoe S, Nakashima S, Matsumoto M et al. Para-aortic lymph node micrometastasis and tumor cell microinvolvement in advanced gastric carcinoma. Gastric Cancer 2, 179-185 (1999).
41. Brennan MF. Lymph node dissection for gastric cancer. N. Engl. J. Med. 340, 956-958(1999).
42. Estes NC, Macdonald JS, Touijer K, Benedetti J, Jacobson J. Inadequate documentation and resection for gastric cancer in the United States: a preliminary report. Am. Surg. 64, 680-685 (1998).
43. White RE, Vezeridis MP. Surgical palliation of gastric cancer. In: Surgery for Gastrointestinal Cancer. Wanebo HJ (Ed.), Lippincott-Raven, Philadelphia, PA, USA, 355-361 (1997).
44. Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E. Gastric cancer. Springer-Verlag, Kanehara, Tokyo. 1-446 (1993).
45. Roder JD, Böttcher K, Siewert JR et al. Prognostic factors in gastric carcinoma. Cancer 72, 2089-2097 (1993).
46. Wanebo HJ, Kennedy BJ, Chmiel J et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann. Surg. 218, 583-592 (1993).
47. Bollschweiler E, Böttcher K, Hölscher AH et al. Is the prognosis for Japanese and German patients with gastric cancer really different? Cancer 71, 2918-2925 (1993).
48. Siewert JR, Sendler A. Potential and futility of sentinel node detection for gastric cancer. Recent Results Cancer Res. 157, 259-269 (2000).
49. Hiratsuka M, Miyashiro I, Ishikawa O et al. Application of sentinel node biopsy to gastric cancer surgery. Surgery 129, 335-340 (2001).
50. Kitagawa Y, Fujii H, Mukai M et al. Radio-guided sentinel node detection for gastric cancer. Br. J. Surg. 89, 604-608 (2002).
51. Kitagawa Y, Ohgami M, Fujii H et al. Laparoscopic detection of sentinel lymph nodes in gastrointestinal cancer: a novel and minimally invasive approach. Ann. Surg. Oncol 8, 86S-89S (2001).
52. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol. 11, 1441-1447(1993).
53. Earle CC, Maronn JA. Adjuvant chemotherapy after curative resection for gastric cancer: revisiting a meta-analysis of randomized trials. Proc. Am. Soc. Clin. Oncol 17, 263a (1998) (Abstract).
54. Mari E, Floriani I, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann. Oncol. 11, 837-843 (2000).
55. Panzini I, Gianni L, Fattori PP et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88, 21-27 (2002).
56. Nashimoto A, Nakajima T, Furukawa H et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J. Clin. Oncol. 21, 2282 (2003).
57. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345, 725-730 (2001).
58. Hagiwara A, Takahashi T, Kojima O et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 339, 629-631 (1992).
59. Faß I, Zengel K, Reinicke T, Jansen M, Schumpelick V. Intraperitoneal therapy with carbon-absorbed mitomycin C in gastric cancer with serosal invasion. J. Cancer Res. Clin. Oncol. 124, (1998).
60. Vanhoefer U, Wilke H, Weh HJ et al. Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann. Oncol. 5, 850-851 (1994).
61. Lowy AM, Mansfield PF, Leach SD et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann. Surg. 229, 303-308 (1999).
62. Ott K, Sendler A, Becker K et al. Neoadjuvant chemotherapy with cisplatin, 5-FU and leucovorin (PLF) in locally advanced gastric cancer: a prospective Phase II study. Gastric Cancer (2003) (In press).
63. Allum WH, Cunningham D, Weeden S (For the UK NCRI Upper GI Clinical Studies Group). Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc. Am. Soc. Clin. Oncol. 22, 998 (2003).
64. Roth AD. Curative treatment of gastric cancer: towards a multidisciplinary approach? Crit. Rev. Oncol Hematol 46, 59-100 (2003).
65. Weiss MM, Kuipers EJ, Postma C et al. Genomic profiling of gastric cancer predicts lymph node status and survival. Oncogene 22, 1872-1879 (2003).
66. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br. J Surg. 75, 110-112 (1988).